- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04312087
Lateral Neck Lymph Node Mapping in Thyroid Cancer
March 16, 2020 updated by: Fudan University
Lateral Neck Lymph Node Mapping in Papillary Thyroid Carcinoma
This study includes papillary thyroid cancer patients who have unpalpable lateral neck lymph nodes but suspicious on ultrasound and/or CT.
Carbon nanoparticles is used as the tracer for lateral neck lymph node mapping.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newly diagnosed papillary thyroid cancer
- The maximum diameter of the thyroid cancer <3 cm with enough normal thyroid tissue for tracer injection
- Unpalpable lateral neck lymph nodes
- Ultrasound and CT showed suspected lateral neck lymph nodes <2 cm
Exclusion Criteria:
- Previously treated thyroid cancer
- High risk thyroid cancer (e.g. with severe extra-adenial invasion or extensive lymph node metastasis or poorly differentiated thyroid cancer)
- Patients with distant metastasis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MLND
Modified lateral neck dissection (compartment II-V) is performed in all patients.
|
Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
|
Experimental: SLNB
Sentinel lymph node biopsy in the lateral neck is performed.
The decision of neck dissection is based on the result of sentinel lymph node biopsy.
|
Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lymph node counts
Time Frame: 1 month after surgery
|
Dyed versus undyed lymph node counts in lateral neck compartments
|
1 month after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lymph node metastasis rate
Time Frame: 1 month after surgery
|
The rate of lymph node metastasis in lateral neck compartments
|
1 month after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2016
Primary Completion (Anticipated)
August 1, 2021
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
March 14, 2020
First Submitted That Met QC Criteria
March 16, 2020
First Posted (Actual)
March 18, 2020
Study Record Updates
Last Update Posted (Actual)
March 18, 2020
Last Update Submitted That Met QC Criteria
March 16, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TC-MAP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Massachusetts General HospitalEli Lilly and CompanyRecruitingThyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland CarcinomaUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
Clinical Trials on Modified lateral neck lymph node dissection
-
Fujian Medical UniversityUnknownThyroid Carcinoma | Endoscopic Surgery | Robot SurgeryChina
-
National Cancer Center, ChinaRecruitingRectal Neuroendocrine NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Peking University First Hospital; Zhejiang Cancer Hospital; Beijing Friendship... and other collaboratorsRecruiting
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompleted
-
West China HospitalTerminated
-
Cancer Institute and Hospital, Chinese Academy...Enrolling by invitationGastrointestinal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Rectal Neoplasms | Lymph Node Metastasis | Oxaliplatin | Cancer of Rectum and AnusChina
-
National Cancer Institute (NCI)TerminatedThyroid Cancer | Low-risk Papillary Thyroid Cancer | Endocrine MalignancyUnited States
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Eastern Hepatobiliary Surgery HospitalUnknownIntrahepatic CholangiocarcinomaChina